Olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation
Urgent opportunity As some of you may know, BCNA provides a consumer comment to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of drugs being considered for subsidy on the PBS. Equity of access to new treatment options is especially important for those with metastatic breast cancer. Our policy team are currently working on a submission for olaparib (Lynparza) for metastatic breast cancer in people with a BRCA gene mutation. Olaparib is a targeted therapy called a PARP inhibitor. It works by making it hard for cancer cells with a BRCA1 or BRCA2 mutation to survive. If you have accessed olaparib privately or have wanted to access it but were unable to due to it not being subsidised and would like to contribute to the BCNA submission, please contact Julie Rae in our policy team: jrae@bcna.org.au today. We use quotes from real people who have experienced the issue to illustrate the points we make in our submissions. Additionally, if you have a known BRCA 1/2 mutation (regardless of whether you have been recommended olaparib) and would like to contribute, please also contact Julie42Views1like0Comments